Nachrichten zur Alvotech Aktie

Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors

Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for…

Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors

Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for…

Wall Street Analysts Think Alvotech (ALVO) Could Surge 72.61%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 72.6% in Alvotech (ALVO). While…

Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million

Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per…

Alvotech Annual General Meeting to be held June 25, 2025

The Annual General Meeting of Alvotech will be held on Wednesday June 25, 2025, at 09.00 a.m. CEST at the…

Alvotech shares surge 6.6% as Q1 results top estimates By Investing.com

Alvotech shares surge 6.6% as Q1 results top estimates…

Alvotech (ALVO) Q4 2024 Earnings Call Transcript

…

Alvotech Reports Record Results for 2024 and Provides Business Update

Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for…

Alvotech Reports Record Results for 2024 and Provides Business Update

REYKJAVIK, Iceland, March 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company…

FDA Accepts RDY & ALVOs Prolia & Xgeva Biosimilar BLA for Review

Dr. Reddy and Alvotech announce the FDA acceptance of the BLA for their proposed biosimilar candidate of Amgens Prolia and…

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company…

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company…

Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024

REYKJAVIK, Iceland, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the…

Alvotechs Position In The Coming Biosimilar Gold Rush

…

Alvotech (ALVO) Q3 2024 Earnings Call Transcript

…

Alvotech (ALVO) Q3 Earnings and Revenues Beat Estimates

Alvotech (ALVO) delivered earnings and revenue surprises of 226.67% and 5.63%, respectively, for the quarter ended September 2024. Do the…

Alvotech application for Prolia/Xgeva biosimilar accepted by EMA

…

Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced…

Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announces…

Alvotech (ALVO) Q2 2024 Earnings Call Transcript

…

Alvotech 2024 Q2 - Results - Earnings Call Presentation

…

Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024

Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for…

European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and…

Alvotech Announces Closing of Private Debt Financing

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today…

Alvotech Issues New Shares to Holders of Convertible Bonds

REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the…

Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today…

Alvotech Receives Conversion Notices for Majority of Convertible Bonds

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today…

Heres Why You Should Consider Buying Alvotech (ALVO) Stock

Here, we discuss some reasons why buying Alvotech (ALVO) stock now may turn out to be a prudent move.…

Alvotech and STADA add to Strategic Alliance through Denosumab Partnership

Alvotech and STADA are strengthening their existing strategic alliance for high-quality, cost-effective biosimilars by extending their partnership to cover AVT03,…

Alvotech enters refinancing agreement with $965M term loan facility

…

Alvotech Announces Strategic Refinancing Agreement

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today…

Alvotech (ALVO) Q1 2024 Earnings Call Transcript

…

Alvotech 2024 Q1 - Results - Earnings Call Presentation

…

Dr. Reddys (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar

Dr. Reddys (RDY) announces entering into a license and supply agreement with Alvotech to develop and commercialize the latters biosimilar…

Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update

REYKJAVIK, Iceland, May 21, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company…

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

REYKJAVIK, ICELAND & PARSIPPANY, NJ — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)…

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

REYKJAVIK, Iceland and PARSIPPANY, N.J., May 21, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva…

Alvotech: Consider Buying As Positive Q1 Earnings Release Likely

…

Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)

REYKJAVIK, Iceland, April 24, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the…

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,…

dpa-AFX ProFeed